ArticleDiscover oncology2025
Pan-cancer analysis of HOMER1 in hepatocellular carcinoma revealing diagnostic potential and immune landscape with experimental validation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHomer scaffold protein 1 (HOMER1), a postsynaptic scaffold protein, regulates excitatory synapses and intracellular signaling and has been implicated in tumorigenesis. This study systematically evaluates the oncogenic roles of HOMER1 through pan-cancer bioinformatics analysis and functional validation in hepatocellular carcinoma (LIHC).
methodsMulti-omics data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Tumor Immune Estimation Resource 2.0 (TIMER 2.0), cBioPortal, UALCAN, and other public databases were integrated to analyze HOMER1 expression profiles, prognostic relevance, epigenetic modifications, and immune infiltration. Drug sensitivity was assessed using Gene Set Cancer Analysis Lite (GSCALite) and DrugBank databases. Protein-protein interaction networks were constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and functionally annotated via Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses. HOMER1 protein expression was validated by immunohistochemistry in LIHC tissues. Cellular assays, including Cell Counting Kit-8 (CCK-8), Transwell migration and invasion assays, wound healing assay, and quantitative polymerase chain reaction (qPCR), were performed to investigate the effects of HOMER1 knockdown on LIHC cell proliferation, migration, and invasion.
resultsPan-cancer analysis revealed that HOMER1 exhibits cancer-type-specific dysregulation and is significantly associated with patient prognosis, DNA methylation, RNA modifications, immune cell infiltration, and immune checkpoint gene expression. HOMER1 expression correlated with anticancer drug sensitivity and was enriched in tumor-promoting pathways such as the peroxisome proliferator-activated receptor (PPAR) signaling pathway. In LIHC, HOMER1 was highly expressed, and its knockdown markedly suppressed hepatoma cell proliferation, migration, and invasion in vitro.
conclusionOur findings demonstrate that HOMER1 functions as a potential oncogene across multiple cancers and actively promotes malignant phenotypes in hepatocellular carcinoma. This study highlights HOMER1 as a promising prognostic biomarker and therapeutic target, providing new insights into cancer prognosis and immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.